New CAR-T therapy shows promise for Hard-to-Treat blood cancers

NCT ID NCT03960840

Ongoing Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new treatment called rapcabtagene autoleucel, a type of CAR-T cell therapy, in adults with certain blood cancers like chronic lymphocytic leukemia (CLL) and diffuse large B-cell lymphoma (DLBCL). Some participants also receive the drug ibrutinib. The goal is to see if the treatment is safe and can shrink or control the cancer. About 217 people are taking part in this early-phase trial.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: rapcabtagene autoleucel (a CAR-T cell therapy) and ibrutinib (a targeted drug)
What this could lead to: If successful, this could offer a new treatment option for people with certain blood cancers that have not responded to other therapies.
What could go wrong: This is an early-phase trial with a small number of participants. The therapy may cause severe side effects, and it is not yet known if it will work better than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute lymphoblastic leukemia B-cell chronic lymphocytic leukemia diffuse large B-cell lymphoma large B-cell lymphoma Precursor Cell Lymphoblastic Leukemia-Lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE LYMPHOBLASTIC LEUKEMIA CHRONIC LYMPHOCYTIC LEUKEMIA DIFFUSE LARGE B-CELL LYMPHOMA LARGE B-CELL LYMPHOMA SMALL LYMPHOCYTIC LYMPHOMA

Contacts and locations

Locations

H Lee Moffitt Cancer Center and Research Institute

Tampa, Florida, 33612, United States
Mass Gen Hosp Cancer Center

Boston, Massachusetts, 02114, United States
Medical College of Wisconsin

Milwaukee, Wisconsin, 53226, United States
Novartis Investigative Site

Melbourne, Victoria, 3000, Australia
Novartis Investigative Site

Melbourne, Victoria, 3004, Australia
Novartis Investigative Site

Vienna, 1090, Austria
Novartis Investigative Site

Marseille, 13273, France
Novartis Investigative Site

Paris, 75475, France
Novartis Investigative Site

Pierre-Bénite, 69495, France
Novartis Investigative Site

Rennes, 35033, France
Novartis Investigative Site

Frankfurt am Main, Hesse, 60590, Germany
Novartis Investigative Site

Leipzig, Saxony, 04103, Germany
Novartis Investigative Site

Bergamo, BG, 24127, Italy
Novartis Investigative Site

Milan, MI, 20132, Italy
Novartis Investigative Site

Rozzano, MI, 20089, Italy
Novartis Investigative Site

Sapporo, Hokkaido, 060-8648, Japan
Novartis Investigative Site

Bunkyo Ku, Tokyo, 1138677, Japan
Novartis Investigative Site

Fukuoka, 8128582, Japan
Novartis Investigative Site

Badalona, Barcelona, 08916, Spain
Novartis Investigative Site

L'Hospitalet de Llobregat, Barcelona, 08907, Spain
Novartis Investigative Site

Barcelona, 08035, Spain
Novartis Investigative Site

Barcelona, 08041, Spain
Novartis Investigative Site

Córdoba, 14004, Spain
Novartis Investigative Site

Madrid, 28009, Spain
Novartis Investigative Site

Madrid, 28041, Spain
Novartis Investigative Site

Salamanca, 37007, Spain
Novartis Investigative Site

Seville, 41013, Spain
Novartis Investigative Site

Valencia, 46010, Spain
Sarah Cannon Research Institute

Nashville, Tennessee, 37221, United States
St Davids South Austin Medical Ctr

Austin, Texas, 78704, United States
Stanford University Medical Center

Stanford, California, 94305-5826, United States
Tennessee Oncology

Nashville, Tennessee, 37203, United States
Uni Of TX MD Anderson Cancer Cntr

Houston, Texas, 77030, United States
Uni of Chi Medi Ctr Hema and Onco

Chicago, Illinois, 60637, United States
University of California LA

Los Angeles, California, 90095, United States
University of Kansas Cancer Center

Westwood, Kansas, 66205, United States
University of Pennsylvania Clinical

Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.